ArticleCureus2025
Ticagrelor-Induced Dermatological Hypersensitivity Reaction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ticagrelor, a potent antiplatelet medication widely used in acute coronary syndromes, is known for its favourable efficacy and safety profile as compared to clopidogrel. However, skin-related adverse events associated with ticagrelor are rare and not extensively reported in the literature. Here we present a 64-year-old male with a history of coronary artery disease and recent ticagrelor initiation following percutaneous coronary intervention. The patient developed a diffuse erythematous rash involving the trunk and extremities, two days post-ticagrelor initiation, prompting a thorough evaluation for drug-induced hypersensitivity reactions. The rash resolved upon discontinuation of ticagrelor and initiation of clopidogrel therapy along with corticosteroids and antihistamines. This case highlights the importance of recognizing dermatology adverse events associated with ticagrelor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.